# A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

> **NCT05931367** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 445 (actual)

## Conditions studied

- Obesity
- Overweight
- Osteo Arthritis Knee

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05931367
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 445 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05931367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05931367, "A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05931367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*